

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>Pestano Gary Anthony</u>			2. Issuer Name and Ticker or Trading Symbol <u>BIODESIX INC [ BDSX ]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ Officer (give title below) <input checked="" type="checkbox"/> Chief Development Officer _____ Other (specify below) _____		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <u>02/23/2021</u>			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person		
2970 WILDERNESS PLACE SUITE 100			4. If Amendment, Date of Original Filed (Month/Day/Year)					
(Street)	(City)	(State)	(Zip)	Rule 10b5-1(c) Transaction Indication <input type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.				
BOULDER	CO	80301						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Options (Right to buy)	\$20.67	02/23/2021		A		25,134		(1)	02/22/2031	Common Stock	25,134	\$0	25,134	D	
Stock Options (Right to buy)	\$20.67	02/23/2021		A		5,155		(2)	02/22/2031	Common Stock	5,155	\$0	5,155	D	
Stock Options (Right to buy)	\$20.67	07/24/2023		D <sup>(3)(4)</sup>		25,134		(1)	02/22/2031	Common Stock	25,134	(3)(4)	0	D	
Stock Options (Right to buy)	\$20.67	07/24/2023		D <sup>(3)(4)</sup>		5,155		(2)	02/22/2031	Common Stock	5,155	(3)(4)	0	D	
Stock Options (Right to buy)	\$13.72	07/24/2023		D <sup>(3)(5)</sup>		1,000		(2)	06/28/2031	Common Stock	1,000	(3)(5)	0	D	
Stock Options (Right to buy)	\$1.2	07/24/2023		A <sup>(3)(4)</sup> <sub>(5)</sub>		6,497		(6)	07/23/2033	Common Stock	6,497	(3)(4)(5)	6,497	D	

Explanation of Responses:

- This option was scheduled to vest in a series of 60 successive, equal monthly installments measured from February 23, 2021.
- This option was fully vested as of the grant date.
- On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than \$10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023.
- The Reporting Person elected to participate in the Tender Offer and received 6,184 Replacement Options with an exercise price of \$1.20 per share in exchange for 30,289 Surrendered Options with an exercise price of \$20.67 per share, after which the Surrendered Options were cancelled.
- The Reporting Person elected to participate in the Tender Offer and received 313 Replacement Options with an exercise price of \$1.20 per share in exchange for 1,000 Surrendered Options with an exercise price of \$13.72 per share, after which the Surrendered Options were cancelled.
- This Replacement Option vests as follows: 3,846 shares of Common Stock underlying this Replacement Option vest on August 1, 2024, and the remaining 2,651 shares of Common Stock underlying this Replacement Option vest in 31 successive, equal monthly installments beginning on August 1, 2024.

/s/ Robin H. Cowie as  
Attorney-in-Fact for Gary Pestano 07/26/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

